Peak Bio, Inc.: 10-Q filed 2021-08-16

Name: Peak Bio, Inc.: 10-Q filed 2021-08-16
Creator: Peak Bio, Inc.

What Peak Bio, Inc. reported in its quarterly report filed 2021-08-16 (fiscal Q2 2021): 20 published measures, 41 facts as tagged in accession 0001206774-21-002187.

This filing

Form: 10-Q (quarterly report)
Filed: 2021-08-16
Fiscal period: fiscal Q2 2021
Accession: 0001206774-21-002187 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Peak Bio, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2021-06-30	58,236,738	USD
At 2020-12-31	107,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit
At 2021-06-30	1,939,609	USD
At 2021-02-01	2,729,200	USD
At 2020-12-31	80,310	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2021-06-30	5,000,009	USD
At 2021-03-31	5,000,002	USD
At 2021-02-01	5,000,001	USD
At 2020-12-31	26,690	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2021-06-30	550,470	USD
At 2020-12-31	25,425	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	616,107	USD	91
2021-01-01 to 2021-06-30	269,924	USD	181
2021-01-01 to 2021-03-31	-346,183	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2021-01-01 to 2021-06-30	-427,045	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2021-01-01 to 2021-06-30	58,452,090	USD	181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-01-01 to 2021-06-30	-57,500,000	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit
At 2021-06-30	269,614	USD
At 2021-02-01	-4,396	USD
At 2020-12-31	-310	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	5,068,102	shares	91
2021-01-01 to 2021-06-30	4,183,046	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	2,219,398	shares	91
2021-01-01 to 2021-06-30	2,053,694	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	0	USD/shares	91
2021-01-01 to 2021-06-30	0	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	0.28	USD/shares	91
2021-01-01 to 2021-06-30	0.13	USD/shares	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	-110,980	USD	91
2021-01-01 to 2021-06-30	-309,421	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2021-06-30	732,393	USD
At 2020-12-31	25,425	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2021-06-30	64,609	USD
At 2020-12-31	80,310	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2021-06-30	0	shares
At 2020-12-31	0	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit
At 2021-06-30	4,730,179	USD
At 2021-02-01	5,004,180	USD
At 2020-12-31	26,846	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2020-12-31	81,575	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2021-06-30	12,656	USD

Inspect the source

Entity: Peak Bio, Inc. / CIK 0001834645
Captured: 2026-09-21T17:30:36.811Z
SEC response SHA-256: fb306ace8ab05628909c7564fe507c4f8c1e9ef794ec2aa905e6b91289f2b6c8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001834645.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))